Catalog No.
EHD48401
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Thr643
Predicted molecular weight
71.67 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P21860
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3
Efficient Design of Affilin® Protein Binders for HER3., PMID:40429825
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors., PMID:40408047
PCSK9 Promotes the Malignancy of Triple-negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3., PMID:40192514
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors., PMID:40178042
Engineered-affibody conjugates contribute to the specific targeting and cellular retention of polyplexes in Erbb3 overexpressed lung cancer cells., PMID:40174661
Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402
Liver-derived Neuregulin1α stimulates compensatory pancreatic β cell hyperplasia in insulin resistance., PMID:40082404
Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth., PMID:39984637
Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma., PMID:39969538
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma., PMID:39937426
CRISPR-Cas12a-Assisted DNA Circuit for Nonmicroscopic Detection of Cell Surface Receptor Clustering., PMID:39924908
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431
Evaluation of co‑inhibition of ErbB family kinases and PI3K for HPV‑negative head and neck squamous cell carcinoma., PMID:39886949
Discovery of CZY43 as a new small-molecule degrader of pseudokinase HER3., PMID:39818014
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma., PMID:39798390
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer., PMID:39794693
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb., PMID:39757718
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling., PMID:39753722
Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer., PMID:39751931
Amiloride sensitizes prostate cancer cells to the reversible tyrosine kinase inhibitor lapatinib by modulating Erbb3 subcellular localization., PMID:39725713
Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer., PMID:39695132
ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new., PMID:39666109
Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy., PMID:39651731
Scleromitrion diffusum (Willd.) R. J. Wang Inhibits Gastric Cancer via ERBB2/ERBB3/PI3K/AKT Pathway., PMID:39549017
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers., PMID:39495173
A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells., PMID:39485069
Immune marker expression and prognosis of early breast cancer expressing HER3., PMID:39447449
Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling., PMID:39393543
HER3: Updates and current biology function, targeted therapy and pathologic detecting methods., PMID:39366553
Investigating the Co-Expression Rate of HER2 and HER3 Biomarkers in Cancer Patients: A Systematic Review and Meta-Analysis., PMID:39342574
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples., PMID:39320886
SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer., PMID:39313574
ESM1 facilitates the EGFR/HER3-triggered epithelial-to-mesenchymal transition and progression of gastric cancer via modulating interplay between Akt and angiopoietin-2 signaling., PMID:39309430
ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity., PMID:39196362
The diabetic myocardial transcriptome reveals Erbb3 and Hspa2 as a novel biomarkers of incident heart failure., PMID:39180332
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate., PMID:39128771
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance., PMID:39098760
Polyoxygenated cembrane-type diterpenes from the Hainan soft coral Lobophytum crassum as a promising source of anticancer agents with ErbB3 and ROR1 inhibitory potential., PMID:39075227
HER3 receptor and its role in the therapeutic management of metastatic breast cancer., PMID:39020378
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response., PMID:38992028
A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance., PMID:38951909
ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia., PMID:38944125
Targeting FTO suppresses hepatocellular carcinoma by inhibiting ERBB3 and TUBB4A expression., PMID:38906227
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer., PMID:38886591
Long road towards effective HER3 targeting in breast cancer., PMID:38885540
Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review., PMID:38851563
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study., PMID:38823410
Trans-activating mutations of the pseudokinase ERBB3., PMID:38806620
HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?, PMID:38760830
For research use only. Not for human or drug use.
